Dirk Eulberg
Overview
Explore the profile of Dirk Eulberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mockel D, Bartneck M, Niemietz P, Wagner M, Ehling J, Rama E, et al.
J Control Release
. 2023 Nov;
365:358-368.
PMID: 38016488
Blood vessel functionality is crucial for efficient tumor-targeted drug delivery. Heterogeneous distribution and perfusion of angiogenic blood vessels contribute to suboptimal accumulation of (nano-) therapeutics in tumors and metastases. To...
2.
Eulberg D, Fromming A, Lapid K, Mangasarian A, Barak A
Front Oncol
. 2022 Dec;
12:1070243.
PMID: 36568151
Multiple mechanisms promote tumor prosperity, which does not only depend on cell-autonomous, inherent abnormal characteristics of the malignant cells that facilitate rapid cell division and tumor expansion. The neoplastic tissue...
3.
Suarez-Carmona M, Williams A, Schreiber J, Hohmann N, Pruefer U, Krauss J, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34607895
Background: Immunotherapy in microsatellite stable colorectal or pancreatic cancer has not shown promising results. It has been hypothesized that targeting immunosuppressive molecules like SDF1-alpha/CXCL12 could contribute to immunotherapy and animal...
4.
Citro A, Pellegrini S, Dugnani E, Eulberg D, Klussmann S, Piemonti L
Am J Transplant
. 2019 Jul;
19(11):3131-3138.
PMID: 31267721
The blockade of pro-inflammatory mediators is a successful approach to improve the engraftment after islet transplantation. L-aptamers are chemically synthesized, nonimmunogenic bio-stable oligonucleotides that bind and inhibit target molecules conceptually...
5.
Haub J, Roehrig N, Uhrin P, Schabbauer G, Eulberg D, Melchior F, et al.
J Invest Dermatol
. 2019 May;
139(10):2144-2153.
PMID: 31039360
Monocytes and monocyte-derived cells are important players in the initiation, progression, and resolution of inflammatory skin reactions. As inflammation is a prerequisite for fibrosis development, we focused on the role...
6.
Bartneck M, Schrammen P, Mockel D, Govaere O, Liepelt A, Krenkel O, et al.
Cell Mol Gastroenterol Hepatol
. 2019 Feb;
7(2):371-390.
PMID: 30704985
Background & Aims: Hepatocellular carcinoma (HCC) typically arises in fibrotic or cirrhotic livers, which are characterized by pathogenic angiogenesis. Myeloid immune cells, specifically tumor-associated macrophages (TAMs), may represent potential novel...
7.
Romoli S, Angelotti M, Antonelli G, Kumar Vr S, Mulay S, Desai J, et al.
Kidney Int
. 2018 Nov;
94(6):1111-1126.
PMID: 30385042
Insufficient podocyte regeneration after injury is a central pathomechanism of glomerulosclerosis and chronic kidney disease. Podocytes constitutively secrete the chemokine CXCL12, which is known to regulate homing and activation of...
8.
Weisberg E, Sattler M, Azab A, Eulberg D, Kruschinski A, Manley P, et al.
Oncotarget
. 2018 Jan;
8(66):109973-109984.
PMID: 29299123
Resistance to targeted tyrosine kinase inhibitors (TKI) remains a challenge for the treatment of myeloid leukemias. Following treatment with TKIs, the bone marrow microenvironment has been found to harbor a...
9.
Devarapu S, Kumar Vr S, Rupanagudi K, Kulkarni O, Eulberg D, Klussmann S, et al.
Clin Immunol
. 2017 Nov;
185:119-127.
PMID: 29111236
Induction therapy of proliferative lupus nephritis still requires the use of unselective immunosuppressive drugs with significant toxicities. In search of more specific drugs with equal efficacy but fewer side effects...
10.
Zboralski D, Hoehlig K, Eulberg D, Fromming A, Vater A
Cancer Immunol Res
. 2017 Oct;
5(11):950-956.
PMID: 28963140
Immune checkpoint inhibitors promote T cell-mediated killing of cancer cells; however, only a subset of patients benefit from the treatment. A possible reason for this limitation may be that the...